Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $16.2 million.

  • Ani Pharmaceuticals' Capital Expenditures rose 26.83% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year decrease of 7.05%. This contributed to the annual value of $16.2 million for FY2024, which is 83.09% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Capital Expenditures stood at $16.2 million for FY2024, which was up 83.09% from $8.9 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Capital Expenditures high stood at $16.2 million for FY2024, and its period low was $2.6 million during FY2021.
  • For the 3-year period, Ani Pharmaceuticals' Capital Expenditures averaged around $11.3 million, with its median value being $8.9 million (2022).
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 58.32% in 2021, then skyrocketed by 247.13% in 2022.
  • Ani Pharmaceuticals' Capital Expenditures (Yearly) stood at $6.1 million in 2020, then tumbled by 58.32% to $2.6 million in 2021, then soared by 247.13% to $8.9 million in 2022, then fell by 0.09% to $8.9 million in 2023, then spiked by 83.09% to $16.2 million in 2024.